Opinion|Videos|June 10, 2024
Natural History of Spinal Muscular Atrophy
Panelists examine the natural history of spinal muscular atrophy (SMA), assessing the characteristic indicators of motor function deterioration and the loss of ambulatory abilities as patients advance in age.
Advertisement
Episodes in this series
- What do we know about the natural history of SMA?
- Discuss decline in motor function and loss of ambulation over time in adults.
Advertisement
Related to this article
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 23, 2026.
The FDA set a first quarter 2027 goal date for troriluzole in spinocerebellar ataxia and plans an advisory committee after a 2025 complete response letter.
Clene has filed an NDA seeking accelerated approval of CNM-Au8 for ALS, following 2 missed primary trial endpoints and years of evolving FDA guidance.
Here's some of what is coming soon to NeurologyLive® this week.
Leonard Dragone, MD, PhD, Disease Area Leader at Johnson & Johnson, discusses how nipocalimab is being incorporated into generalized MG care, what long-term data show, and where J&J sees the therapy’s role evolving.
Pivotal AFFINITY DUCHENNE results showed microdystrophin expression above the prespecified threshold in 93% of evaluable participants, with preliminary functional findings favoring treatment over external controls.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 16, 2026.
Three-year extension data from the phase 3 IB1001-301 trial show levacetylleucine slowed disease progression in both adults and children with Niemann-Pick disease type C.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
FDA Accepts Troriluzole NDA Resubmission for Spinocerebellar Ataxia
2
Remibrutinib Lowers Relapse Rate vs Teriflunomide in Relapsing MS
3
Real-World Data Show Switch to Subcutaneous Ocrelizumab Well Tolerated
4
Early Data Show Dual-Targeting CAR-T Agent CTA313 Stabilizes Progressive Multiple Sclerosis
5